Published June 26, 2019 | Version v1
Journal article Open

Microbiota y síndrome de intestino irritable

Creators

  • 1. Universidad Autónoma de Querétaro, Campus Juriquilla, Querétaro, México
  • 2. Centro de Investigaciones en Ciencias Microbiológicas, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla, México
  • 3. Universidad Nacional Autónoma de México, Ciudad de México, México
  • 4. Universidad Autónoma del Estado de Hidalgo, Instituto de Ciencias Agropecuarias, Hidalgo, México
  • 5. Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, México

Description

RESUMEN

El síndrome de intestino irritable (SII) es una enfermedad inflamatoria gastrointestinal sistémica que afecta la absorción de macro y micronutrientes, esta enfermedad es encontrada regularmente en personas adultas, rara vez en niños, sin embargo, no se descarta su presencia en este rango de edad. El SII tiene diferentes orígenes donde el equilibrio de la población de los microorganismos intestinales, influye significativamente a la evolución de esta enfermedad. Este equilibrio de la microbiota, dependerá de la presencia de patógenos provenientes de la mala calidad de higiene en los alimentos, malos hábitos; bajo consumo de probióticos y prebióticos en la dieta; incremento en el consumo de antibióticos; consumo desmedido de bebidas alcohólicas, medicamentos; el hábito frecuente de fumar; estrés exacerbado, inactividad física, padecer enfermedades crónicas o genéticas. Cuando no se detecta oportunamente esta enfermedad y no hay un apropiado tratamiento multidisciplinario para el control de la sintomatología, la mayoría de las veces la calidad de vida de los pacientes que la padecen desmejora notablemente, o bien, puede evolucionar negativamente en atrofia intestinal e inclusive cáncer de colon. En la presente revisión se aborda además, la influencia que puede tener la microbiota en la disminución de trastornos secundarios del SII y algunas inclusiones de recomendaciones nutricionales y sus posibles efectos sobre la salud y recuperación del paciente que la padece.

 

ABSTRACT

Irritable bowel syndrome (IBS) is a systemic inflammatory gastrointestinal disease that interferes with the absorption of macro and micronutrients from food, this disease is regularly reported in adults, but it is rarely found in children, however, it is not ruled out its presence in this range of age. IBS has different origins where the balance of the intestinal microorganisms population significantly influences the disease evolution. This balance of the microbiota will depend on the presence of pathogens coming from the inadequate and / or poor quality and hygiene of food, low consumption of probiotics and prebiotics, drugs use, smoking habits, antibiotics consumption, alcohol intake, exacerbated stress, physical inactivity and chronic and genetic diseases. When the disease is no detected early and it does not have an appropriate multidisciplinary treatment for symptoms control, this may involve to impairment quality life, even more the patient may progress to intestinal atrophy or colon cancer. The present review addresses the effect of the microbiota on the reduction of adverse effects and, it describes some of the nutritional recommendations and the effects on health and recovery of the patient in a comprehensive manner.

Files

B 4(14) Alatorre et al 2019 1-10.pdf

Files (2.9 MB)

Name Size Download all
md5:c53145293e5c0113d37174b48ad5c7c8
2.9 MB Preview Download

Additional details

Identifiers

ISSN
2594-0627
URL
https://www.aytbuap.mx/aytbuap-414/microbiota-y-s%C3%ADndrome-de-intestino-irritable
URL
https://eoi.citefactor.org/10.11235/BUAP.04.14.01

Related works

Is identical to
Journal article: https://repositorioinstitucional.buap.mx/handle/20.500.12371/9329 (URL)

References

  • Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: properties, examples, and specific applications. Coid Spring Harb. Perspect. Med. 2013; 3(3): 1-15.
  • GMFH Editing Team. Microbiota intestinal, News Watch ES. 2012 [Internet]. [Consultado el 1 Jun 2019].
  • Lañe ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: Current and therapeutic insights. J. Inflamm Res. 2017; 10: 63-73.
  • Caputi, V., Girón, M.C. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease. Int. J. Mol. Sel. 2018; 19(6): 1689.
  • Goodrich JK, Di Rienzi SC, Poole AC, Koren O, Walters WA, Caporaso JG, Knight R, Ley RE. Conducting a microbiome study. Cell. 2014; 158: 250-262.
  • Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012; 489:250-256.
  • Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas M, Eggersdorfer M. The role of the microbiome for human health: From basic Science to clinical applications. Eur. J. Nutr. 2018; 57: 1-14.
  • Schmulson MJ, Drossman DA. What is New ¡n Rome IV. J. Neurogastroenterol. Motil. 2017; 23 (2): 151-153.
  • Ford AC, Lacy BE, Talley NK. Irritable Bowel Syndrome. N. Engl. J. Med. 2017; 26: 2566-2578.
  • Rothschild D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018.
  • Carroll M, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea- predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:521-530.
  • Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M. Gut Microbiota and Cáncer: From Pathogenesis to Therapy. Cancers. 2019; 11(1):38
  • Saulnier DM, Riehle K, Mistretta T-A., Díaz M.- A, Mandal D, Raza S, Weidler EM, (...), Versalovic J. Gastrointestinal microbiome signaturas of pediatric patients with irritable bowel syndrom. Gastroenterology, 2011. 141 (5):1782-1791.
  • Rajiliü-Stojanoviü M, Biagi E, Heilig HG, Kajander K, Kekkonen RA. Tims S, de Vos W. Global and Deep Molecular Analysis of Microbiota Signaturas in Fecal Samples From Patients With Irritable Bowel Syndrome. Gastroenterology. 2011; 141(5): 1792-1801.
  • Figueroa C. Dieta baja en FODMAP en el síndrome de intestino irritable. Rev. Med. Clin. Condes. 2015; 26:628-633.
  • Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibra and FODMAPÜrestricted diet in the management of constiparon and irritable bowel syndrome. Aliment. Pharmacol. Ther. 2015; 41(12): 1256-1270.
  • Trinkley KE, PharmD MC, Nahata MC, PharmD MS. Treatment of irritable bowel syndrome. J. Clin. Pharm. Ther. 2010; 36: 275-282.
  • Gibson PR, Shepherd SJ. Food cholee as a key management strategy for functional gastrointestinal symptoms. Am. J. Gastroenterol. 2012; 107: 657
  • Bóhn L, Stórsrud S, Tórnblom H, Bengtsson U, Simrén M. Self reported food-related gastrointestinal symptoms in IBS are common and associated with more severa symptoms and reduces quality of life. Am. J. Gastroenterol. 2013; 108: 634-641.
  • Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR. Gluten causes gastrointestinal symptoms in subjeets without celiac disease: a double-blind randomized placebo-controlled trial. Am. J. Gastroenterol. 2010; 106: 508-14.
  • Occhipinti K, Smith JW. Irritable Bowel Syndrome: A Review and Update. Clin. Colon Rectal Surg. 2012; 25:46-52.
  • Eiden KA. Nutritional considerations ¡n inflammatory bowel disease. Practical Gastro. 2003; 27(5): 33-54.
  • Caballero S, Pamer EG. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu. Rev. Immunol. 2015; 33: 227-256.
  • Morales P, Brignardello J, Gotteland M. La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad. Rev Med Chile. 2010; 138: 1020-1027.
  • Gurevich KG1, Nikonov EL2, Zaborova VA3, Shelekhova TY3, Zolnikova OY3. Probiotic using as a part of complex therapy of disbiotic violations at some intestinal diseases. Vopr. Pitan. 2019; 88(l):77-84.
  • Alarcón P, González M, Castro É. Rol de la microbiota gastrointestinal en la regulación de la respuesta inmune. Rev Med Chile. 2016; 144(7): 910-916
  • Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat. Rev. Microbiol. 2010; 8: 656-67. Stokes MA. Crohn's disease and nutrition. Br. J. Surg. 1992; 79:391.
  • Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Am. J. Gastroenterol. 2015; 28: 203-209
  • Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J. Neurogastroenterol. Motil. 2016; 22: 558-574.